Patent NZ-335973-A (NZ)
Title: Indane or dihydroindole derivatives and their use in treating neurological and cardiovascular disorders
Inventor: PERREGAARD JENS K
IPC: G11C5/02
Filed: 1997-12-19
Abstract: A substituted indane or dihydroindole compound of Formula I wherein A is a group selected from (a), (b) or (c), Y is a hydrocarbon group completing an indane ring, a NR1 group that completes a dihydroindole ring, or an N group that completes a dihydroindole ring linked via the 1-position; W is a bond, and n+m is 1, 2, 3, 4, 5, or 6; W is CO, SO, or S02, n is 2, 3, 4, or 5 and m is 0, 1, 2, or 3, provided that n+m is not more than 6; or W is O, S, n is 2, 3, 4, or 5 and m is 0,1, 2, or 3, provided that n+m is not more than 6, and provided that if Y is N completing a dihydroindole ring attached via the 1-position then m is 2, or 3; and if Y is NR1 completing a dihydroindole ring linked via the 2-position then m is 1, 2, or 3; The dotted line, emanating from X, indicates an optional bond; when it does not indicate a bond, X is N, CH or COH; and when it indicates a bond, X is C; R1 is hydrogen, C1-6alk(en/yn)yl, C3-8-cycloalk(en)yl, C3-8-cycloalk(en)yl-C1-6-alk(en/yn)yl, aryl, heteroaryl, aryl-C1-6-alkyl, heteroaryl-C1-6-alkyl, acyl, thioacyl, C1-6-alkylsulfonyl, trifluoromethylsulfonyl, arylsulfonyl, or heteroarylsulfonyl; R15VCO- wherein V is O or S and R15 is C1-6-alk(en/yn)yl, C3-8-cycloalk(en)yl, C3-8-cycloalk(en)yl-C1-6-alk(en/yn)yl, aryl, or heteroaryl; or a group R16R17NCO- or R16R17NCS- wherein R16 and R17 are independently hydrogen, C1-6-alk(en/yn)yl, C3-8-cycloalk(en)yl, C3-8-cycloalk(en)yl-C1-6-alk(en/yn)yl, heteroaryl, or aryl, or R16 and R17 together with the N-atom to which they are linked, form a pyrrolidinyl, piperidinyl or perhydroazepin group; R2-R5 are independently selected from hydrogen, halogen, cyano, nitro, C1-6-alk(en/yn)yl, C1-6alkoxy, C1-6-alkylthio, hydroxy, C3-8-cycloalk(en)yl, C3-8-cycloalk(en)yl-C1-6-alk(en/yn)yl, C1-6-alkylcarbonyl, phenylcarbonyl, halogen substituted phenylcarbonyl, trifluoromethyl, trifluoromethylsulfonyloxy and C1-6alkylsulfonyl, one of R2-R5 alternatively being a group NR13R14 wherein R13 is as defined for R1 and R14 is hydrogen, C1-6-alk(en/yn)yl, C3-8 cycloalk(en)yl, C3-8-cycloalk(en)yl-C1-6 alk(en/yn)yl, aryl, heteroaryl, aryl-C1-6 alkyl, or heteroaryl-C1-6-alkyl, or R13 and R14 together with the N-atom to which they are linked, form a group as disclosed in (d). wherein Q is C=O, C=S or CH2; T is NH, N-alkyl, S, O or CH2; p is 1-4, inclusive; or two adjacent groups taken from R2 - R5 may be joined and designate a -(CH2)3-, or -CH=CH-NH-, thereby forming a fused 5 membered ring; R6-R9, R11 and R12 are independently hydrogen, halogen, cyano, nitro, C1-6-alk(en/yn)yl, C1-6-alkoxy, C1-6-alkylthio, hydroxy, C3-8-cycloalk(en)yl, C3-8-cycloalk(en)yl-C1-6 alk(en/yn)yl, aryl, heteroaryl, phenylcarbonyl, halogen substituted phenylcarbonyl, trifluoromethyl, or C1-6 alkylsulfonyl, or two adjacent groups taken from R6 - R9 may together form a methylenedioxy group; R10 is as defined for R1 above; with the proviso that the substituent R3 or R4 in position 6 may not be -NR13R14 when Y is CH2 W is a bond, n+m is 1 and the ring is linked via the 1-position;  Also disclosed is the use of the above compound in the manufacture of a medicament useful in the treatment of positive and negative symptoms of schizophrenia, other psychoses, anxiety disorders, such as generalised anxiety disorder, panic disorder, and obsessive compulsive disorder, depression, alcohol abuse, impulse control disorders, aggression, side effects induced by conventional antipsychotic agents, ischaemic disease states, migraine, senile dementia and cardiovascular disorders and in the improvement of sleep.